Summit Therapeutics' Ivonescimab targets non-small cell lung cancer through its dual anti-PD-1 plus anti-VEGF mechanism.
ModMed®, a leader in specialty-specific healthcare technology, today announced its product roadmap for delivering the AI-Powered Practice, bringing powerful AI tools to all areas of specialty medical ...
Gilead Sciences, Inc. today announced the delivery of first shipments of lenacapavir ? Gilead's twice-yearly injectable HIV-1 capsid inhibitor ? for the prevention of HIV as pre-exposure prophylaxis ...
Jan Schellens is a medical oncologist and clinical pharmacologist by training, he previously served as staff member of the Department of Medical Oncology, as Head of the Department of Clinical ...
The Global Electronic Data Capture Software Market Size projected to grow at a CAGR of 14.5% from 2024 to 2031, according to a new report published by Verified Market Research®. The report reveals ...
Strategy Inc. (NASDAQ: MSTR) disclosed an $835.6 million Bitcoin (CRYPTO: BTC) purchase for the week ending Nov. 16 as Tom ...
ReCode Therapeutics, a clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, today announced that the U.S. Food and ...
It will be the first of a new range of models to wear JLR's Freelander badge; they will at first be sold only in China ...
Operator: Good morning, ladies and gentlemen, and welcome to Scholar Rock’s Third Quarter 2025 Conference Call. [Operator ...
She said there was a “clear regional benefit” to the Bay of Plenty. The region has significant seasonal work industries, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback